| 查看: 4175 | 回复: 17 | |||||
[交流]
达比加群酯的SWOT分析项
|
|||||
|
老大让我做一个SWOT分析，这对一个没有THOMSON、没有Pharmaproject的立项工作者来说，只能空手套白狼了，暂时只想出以下几个分析项，请各位虫友补充啦。 S分析 用药方法的便利性 出血安全性得到FDA、EMA等机构的屡次肯定 曾经获得FDA下属委员会全票支持 其对卒中的预防效果明显优于华法林 有间接比较研究显示，达比加群酯的成本-效益特征与有效性特征优于利伐沙班 先后在德国和加拿大被授予Prix Galien最佳药物奖 曾经获得NICE的有条件推荐 上市后市场表现强劲，已经实现了重磅炸弹级别的销售额 W分析 出血事件—达比加群酯挥之不去的阴影 肾功能损伤与P-gp是达比加群酯在其用药过程中需要调整剂量的主要因素 RE-ALLGN失败，使得人工心脏瓣膜成为达比加群酯的禁忌症之一 价格昂贵 O分析 适应证发病率高，用药市场规模庞大 需要开发新的药物，以弥补华法林的不足 利伐沙班于ROCKET-AF试验中仅证实与华法林相比的非劣性 T分析 将面临来自阿哌沙班、利伐沙班、依度沙班的激烈竞争 [ Last edited by williamxiang on 2013-4-3 at 16:31 ] |
回复此楼» 收录本帖的淘帖专辑推荐
 研发工艺 | 泮托拉唑 |
» 猜你喜欢
求蛋白推荐，用于实验教学中蛋白药物的表达
已经有0人回复
-
求蛋白推荐，用于实验教学中蛋白药物的表达
已经有2人回复
-
药理学论文润色/翻译怎么收费?
已经有186人回复
-
SUES&NERCN课题组接受硕士生调剂 (学硕1名+专硕1名)
已经有0人回复
-
342一志愿大工制药专硕，本科211，求调剂
已经有2人回复
-
SUES&NERCN课题组接受硕士生调剂 (学硕1名+专硕1名)
已经有0人回复
-
SUES&NERCN课题组接受硕士生调剂 (学硕1名+专硕1名)
已经有0人回复
-
医药研发数据库资源
已经有4人回复
-
26申博-药化方向
已经有1人回复
-
求大佬收留
已经有0人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 达比加群酯在中国获批
已经有17人回复
- 达比加群酯经过碱降解后产物会是什么结构？
已经有10人回复
- 达比加群酯甲磺酸盐 颜色
已经有10人回复
» 抢金币啦！回帖就可以得到:
-
江西理工大学2026年博士研究生招生报名公告（第二批次），可以联系马胜灿老师
+2/900
-
【通知】北京信息科技大学仪器科学与光电工程学院招收博士研究生（2026）
+1/83
-
北京航空航天大学-仿生界面材料科学全国重点实验室郭林院士团队诚聘博士后
+1/83
-
面上祈福
+1/77
-
87 年东北人定居苏州寻找良缘
+1/75
-
兰州新区化工产业招商引资
+1/71
-
西交利物浦大学招收26年12月入学奖学金博士生1名（人机协作康复的交互式数字孪生）
+1/34
-
【通知】北京信息科技大学仪器科学与光电工程学院招收调剂生（2026），快来报名吧！
+1/32
-
康复大学神经肌肉康复工程团队诚聘博士后/科研助理——多模态生理感知与智能穿戴方向
+1/32
-
湖南师范大学（211，双一流）-有机化学-申请审核制博士招生
+1/31
-
【博士招生】江西理工大学招收博士研究生
+1/28
-
浙江理工大学国家级高层次人才团队招收能源光电催化材料方向博士生(截止5月31号)
+2/22
-
【通知】北京信息科技大学仪器科学与光电工程学院招收博士研究生（2026）
+2/18
-
“双一流”南京邮电大学--海优团队--招收2026博士生1-2名（6月15日前有效）
+1/12
-
电力全国重点实验室双一流A类长江学者团队补招26年全日制学术博士1名（6月2日截止）
+2/10
-
上海大学微电子学院杨军教授团队招聘带编专任教师
+1/7
-
快捡漏！北京信息科技大学光电学院2026博士研究生招生中！
+1/6
-
上海交通大学化学化工学院张智涛课题组诚聘博士后
+1/5
-
哈尔滨工业大学/院士团队招收 硕士、博士
+1/4
-
成果鉴定/职称评审/高企认定，科技查新该怎么避坑？
+1/3
★ ★ ★ ★ ★ ★ ★ ★
小木虫: 金币+0.5, 给个红包，谢谢回帖
痴夷子皮: 金币+2, 谢谢交流，欢迎常来哦。 2013-04-07 08:32:30
williamxiang: 金币+5 2013-04-07 09:53:30
小木虫: 金币+0.5, 给个红包，谢谢回帖
痴夷子皮: 金币+2, 谢谢交流，欢迎常来哦。 2013-04-07 08:32:30
williamxiang: 金币+5 2013-04-07 09:53:30
|
楼上的就是来自TP中达比加群酯的SWOT分析。 给楼主个站内链接：http://muchong.com/bbs/viewthread.php?tid=5319066 建议：做产品SWOT分析的时候可结合国内情况，行业情况及本公司情况三级，给出相应的分析。 楼主对这个产品所述的SWOT分析，已相当专业了！除了专业方面的应该还有些上述建议的其他的。 个人意见，仅供参考！ |
9楼2013-04-04 00:12:48
★ ★ ★
小木虫: 金币+0.5, 给个红包，谢谢回帖
痴夷子皮: 金币+2, 谢谢交流，欢迎常来哦。 2013-04-07 08:32:18
小木虫: 金币+0.5, 给个红包，谢谢回帖
痴夷子皮: 金币+2, 谢谢交流，欢迎常来哦。 2013-04-07 08:32:18
|
Strengths The first novel anticoagulant to secure approval for stroke prevention in atrial fibrillation (AF), entering the US market in November 2010 No requirement for anticoagulation monitoring and dose adjustment, and no food effect In the RE-LY trial in AF, Pradaxa showed comparable to superior efficacy in stroke prevention, compared with warfarin, with equal to lower bleeding risk A subgroup analysis from RE-LY showed that Pradaxa 150 mg bid reduced the rate of stroke by 35% compared with well-controlled warfarin, irrespective of a patient's stroke risk Comparable to Lovenox in the prevention of major venous thromboembolism (VTE) and VTE-related mortality after both knee and hip replacement, according to RE-NOVATE data Equal efficacy to well-controlled warfarin in the treatment of acute VTE, but with a 37% reduction in major or clinically relevant bleeding risk over 6 months, according to RECOVER data |
2楼2013-04-03 10:38:46
13楼2013-04-09 19:00:34
★ ★ ★ ★ ★ ★
小木虫: 金币+0.5, 给个红包，谢谢回帖
williamxiang: 金币+5 2013-04-03 10:47:53
小木虫: 金币+0.5, 给个红包，谢谢回帖
williamxiang: 金币+5 2013-04-03 10:47:53
|
Weaknesses A superiority claim over warfarin in stroke prevention was rejected for inclusion in the label by the FDA A 110 mg doseage was not approved for use in patients at higher bleeding risk A higher risk of myocardial infarction was seen in RE-LY Twice daily dosing, compared with once daily for Xarelto Not approved in the US for VTE prevention post-surgery, unlike Xarelto which was approved in July 2011 Has faced some safety concerns, and the label was updated to mandate renal testing in high-risk patients Associated with a 6% rate of major gastrointestinal hemorrhage during each patient year on treatment Other gastrointestinal side effects, including dyspepsia, nausea and gastritis, are increased compared with warfarin (35% vs 24%) Current lack of antidote Very short half-life once removed from specially designed desiccant-containing packaging |
3楼2013-04-03 10:41:12
★
小木虫: 金币+0.5, 给个红包，谢谢回帖
小木虫: 金币+0.5, 给个红包，谢谢回帖
|
Opportunities Approval in AF opens up a blockbuster market, and Pradaxa could garner a greater share of the market in the near term due to its first mover advantage Pradaxa could be viewed as superior to Xarelto given Xarelto's lack of superiority to warfarin on an intent-to-treat basis seen in the ROCKET AF trial Despite the proven efficacy of warfarin in stroke prevention, it has a number of limitations, such as an increased risk of bleeding and the need for patient monitoring and dose adjustment, which has created an unmet need for safe and effective alternatives Approval in acute coronary syndrome (ACS); phase III trials in this setting began in December 2007 Development of competitor Eliquis in ACS was discontinued following high rates of bleeding in trials High cost and considerable copay required for Pradaxa may fade as insurers realize potential savings from increased avoidance of ischemic events and hospitalization AF is the most common sustained cardiac rhythm disturbance, and prevalence increases with age Up to 60% of cases of AF are caused by hypertension or coronary artery disease, which are increasing in prevalence in most Western societies ACS is the leading cause of death in the US and one of the most prevalent non-communicable diseases in the world |
4楼2013-04-03 10:53:35
★ ★ ★ ★
williamxiang: 金币+4 2013-04-03 13:01:31
williamxiang: 金币+4 2013-04-03 13:01:31
|
Threats Commercial threat from Eliquis; current phase III data appear to support a superiority claim over warfarin which would differentiate the product Increased competition in the oral anticoagulant category; the marketing battle between Pradaxa, Xarelto and Eliquis will be key In Japan, Lixiana is in development for stroke prevention in AF, and could present competition in this market following Pradaxa's launch in March 2011 The drug may not gain approval in ACS given concerns about bleeding If approved, use in ACS may be limited given the availability of new, more potent antiplatelet regimes, such as AstraZeneca's Brilinta, that improve outcomes with less increased bleeding Physicians may be reluctant to switch patients who are well controlled on warfarin to other treatment options Price: the significant price difference between Pradaxa and warfarin could present reimbursement issue Self administration of low-molecular-weight heparins out of hospital by patients with AF undergoing elective cardioversion is a promising approach that may result in cost savings Low-molecular-weight heparins, in particular enoxaparin which presents a generic and efficacious option for DVT treatment and prophylaxis following orthopedic surgery |
5楼2013-04-03 10:54:50
6楼2013-04-03 10:56:14
7楼2013-04-03 11:15:17
8楼2013-04-03 13:02:42
10楼2013-04-04 00:54:08
11楼2013-04-06 12:19:13
12楼2013-04-06 21:54:49
14楼2013-04-10 00:30:10
15楼2013-04-11 20:08:46
16楼2013-04-26 06:35:02
17楼2013-09-03 16:57:58
18楼2013-09-10 18:04:01